SG11201901995TA - Crystalline and salt forms of ppar agonist compounds - Google Patents
Crystalline and salt forms of ppar agonist compoundsInfo
- Publication number
- SG11201901995TA SG11201901995TA SG11201901995TA SG11201901995TA SG11201901995TA SG 11201901995T A SG11201901995T A SG 11201901995TA SG 11201901995T A SG11201901995T A SG 11201901995TA SG 11201901995T A SG11201901995T A SG 11201901995TA SG 11201901995T A SG11201901995T A SG 11201901995TA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- english
- pct
- applicant
- salt forms
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
- C07D233/60—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms with hydrocarbon radicals, substituted by oxygen or sulfur atoms, attached to ring nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662404474P | 2016-10-05 | 2016-10-05 | |
| PCT/US2017/055403 WO2018067860A1 (fr) | 2016-10-05 | 2017-10-05 | Formes cristallines et salines de composés agonistes de ppar |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201901995TA true SG11201901995TA (en) | 2019-04-29 |
Family
ID=60153508
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201901995TA SG11201901995TA (en) | 2016-10-05 | 2017-10-05 | Crystalline and salt forms of ppar agonist compounds |
Country Status (31)
| Country | Link |
|---|---|
| US (3) | US10927094B2 (fr) |
| EP (1) | EP3523283B1 (fr) |
| JP (1) | JP7017563B2 (fr) |
| KR (1) | KR20190057129A (fr) |
| CN (1) | CN109843857B (fr) |
| AU (1) | AU2017340763B2 (fr) |
| BR (1) | BR112019006030A2 (fr) |
| CA (1) | CA3036587A1 (fr) |
| CO (1) | CO2019003162A2 (fr) |
| CY (1) | CY1124655T1 (fr) |
| DK (1) | DK3523283T3 (fr) |
| ES (1) | ES2887008T3 (fr) |
| HR (1) | HRP20211341T1 (fr) |
| HU (1) | HUE055678T2 (fr) |
| IL (1) | IL265730B (fr) |
| JO (1) | JOP20190039B1 (fr) |
| LT (1) | LT3523283T (fr) |
| MA (1) | MA46460A (fr) |
| MX (1) | MX2019003945A (fr) |
| MY (1) | MY202008A (fr) |
| PH (1) | PH12019500727A1 (fr) |
| PL (1) | PL3523283T3 (fr) |
| PT (1) | PT3523283T (fr) |
| RS (1) | RS62245B1 (fr) |
| RU (1) | RU2759724C2 (fr) |
| SG (1) | SG11201901995TA (fr) |
| SI (1) | SI3523283T1 (fr) |
| TW (1) | TWI769182B (fr) |
| UA (1) | UA124770C2 (fr) |
| WO (1) | WO2018067860A1 (fr) |
| ZA (1) | ZA201901744B (fr) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2325171B1 (fr) | 2005-05-26 | 2013-10-09 | Aldexa Therapeutics, Inc. | Dérivés de quinoline pour le traitement des maladies rétiniennes |
| CN108349904B (zh) * | 2015-10-07 | 2021-08-31 | 米托布里奇公司 | Ppar激动剂、化合物、药物组合物及其使用方法 |
| CA3036587A1 (fr) | 2016-10-05 | 2018-04-12 | Mitobridge, Inc. | Formes cristallines et salines de composes agonistes de ppar |
| CN111356451A (zh) | 2017-10-10 | 2020-06-30 | 奥尔德拉医疗公司 | 炎性病症的治疗 |
| WO2020033344A1 (fr) * | 2018-08-06 | 2020-02-13 | Aldeyra Therapeutics, Inc. | Composés polymorphes et leurs utilisations |
| US20220031666A1 (en) * | 2018-10-23 | 2022-02-03 | Japan Science And Technology Agency | PPARo ACTIVATOR |
| AU2022286415A1 (en) | 2021-06-02 | 2023-12-14 | Astellas Pharma Inc. | Methods of use of ppar agonist compounds and pharmaceutical compositions thereof |
| WO2023147309A1 (fr) | 2022-01-25 | 2023-08-03 | Reneo Pharmaceuticals, Inc. | Utilisation d'agonistes ppar-delta dans le traitement d'une maladie |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004063165A1 (fr) | 2003-01-06 | 2004-07-29 | Eli Lilly And Company | Derive de pyrazole utilise comme modulateur du recepteur ppar |
| EP1671633A1 (fr) | 2004-12-17 | 2006-06-21 | Sanofi-Aventis Deutschland GmbH | Utilisation de PPAR agonistes pour traiter l'insuffisance cardiaque congestive |
| JP2008528700A (ja) * | 2005-02-03 | 2008-07-31 | アイアールエム・リミテッド・ライアビリティ・カンパニー | Ｐｐａｒモジュレーターとしての化合物および組成物 |
| CN101296892A (zh) * | 2005-09-07 | 2008-10-29 | 普莱希科公司 | Ppar活性化合物 |
| DE102006023336A1 (de) * | 2006-05-18 | 2007-11-22 | Merck Patent Gmbh | 1,5-Diphenyl-pyrazole II |
| FR2940289B1 (fr) * | 2008-12-23 | 2014-09-12 | Biopharmed | Derives de la classe des hydroxyquinoleines aminees pour le traitement du cancer du pancreas |
| CN102727489A (zh) * | 2012-07-18 | 2012-10-17 | 西南大学 | 5-芳(杂环)亚甲基噻唑烷-2，4-二酮在制备ppar激动剂中的应用 |
| WO2016057658A1 (fr) | 2014-10-08 | 2016-04-14 | Mitobridge, Inc. | Agonistes de ppar, composés, compositions pharmaceutiques et méthodes d'utilisation de ceux-ci |
| CN108349904B (zh) * | 2015-10-07 | 2021-08-31 | 米托布里奇公司 | Ppar激动剂、化合物、药物组合物及其使用方法 |
| CA3019014A1 (fr) | 2016-04-13 | 2017-10-19 | Mitobridge, Inc. | Agonistes de ppar, composes, compositions pharmaceutiques et methodes d'utilisation de ceux-ci |
| PL3522880T3 (pl) * | 2016-10-05 | 2021-08-23 | Mitobridge, Inc. | Sposoby leczenia ostrego uszkodzenia nerek |
| CA3036587A1 (fr) | 2016-10-05 | 2018-04-12 | Mitobridge, Inc. | Formes cristallines et salines de composes agonistes de ppar |
-
2017
- 2017-10-05 CA CA3036587A patent/CA3036587A1/fr active Pending
- 2017-10-05 CN CN201780062034.5A patent/CN109843857B/zh active Active
- 2017-10-05 SI SI201730879T patent/SI3523283T1/sl unknown
- 2017-10-05 AU AU2017340763A patent/AU2017340763B2/en active Active
- 2017-10-05 PT PT177877743T patent/PT3523283T/pt unknown
- 2017-10-05 IL IL265730A patent/IL265730B/en unknown
- 2017-10-05 HU HUE17787774A patent/HUE055678T2/hu unknown
- 2017-10-05 EP EP17787774.3A patent/EP3523283B1/fr active Active
- 2017-10-05 BR BR112019006030A patent/BR112019006030A2/pt active Search and Examination
- 2017-10-05 MA MA046460A patent/MA46460A/fr unknown
- 2017-10-05 KR KR1020197012668A patent/KR20190057129A/ko not_active Application Discontinuation
- 2017-10-05 RS RS20211042A patent/RS62245B1/sr unknown
- 2017-10-05 WO PCT/US2017/055403 patent/WO2018067860A1/fr active Application Filing
- 2017-10-05 US US16/334,746 patent/US10927094B2/en active Active
- 2017-10-05 UA UAA201903678A patent/UA124770C2/uk unknown
- 2017-10-05 LT LTEPPCT/US2017/055403T patent/LT3523283T/lt unknown
- 2017-10-05 JO JOP/2019/0039A patent/JOP20190039B1/ar active
- 2017-10-05 ES ES17787774T patent/ES2887008T3/es active Active
- 2017-10-05 TW TW106134298A patent/TWI769182B/zh active
- 2017-10-05 JP JP2019518286A patent/JP7017563B2/ja active Active
- 2017-10-05 PL PL17787774T patent/PL3523283T3/pl unknown
- 2017-10-05 MX MX2019003945A patent/MX2019003945A/es unknown
- 2017-10-05 MY MYPI2019001560A patent/MY202008A/en unknown
- 2017-10-05 SG SG11201901995TA patent/SG11201901995TA/en unknown
- 2017-10-05 RU RU2019110736A patent/RU2759724C2/ru active
- 2017-10-05 DK DK17787774.3T patent/DK3523283T3/da active
-
2019
- 2019-03-20 ZA ZA2019/01744A patent/ZA201901744B/en unknown
- 2019-03-29 CO CONC2019/0003162A patent/CO2019003162A2/es unknown
- 2019-04-03 PH PH12019500727A patent/PH12019500727A1/en unknown
-
2021
- 2021-02-19 US US17/179,604 patent/US11530192B2/en active Active
- 2021-08-20 HR HRP20211341TT patent/HRP20211341T1/hr unknown
- 2021-08-31 CY CY20211100775T patent/CY1124655T1/el unknown
-
2022
- 2022-12-16 US US18/082,847 patent/US11912681B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201901995TA (en) | Crystalline and salt forms of ppar agonist compounds | |
| SG11201807784SA (en) | 3-desoxy derivative and pharmaceutical compositions thereof | |
| SG11201909963YA (en) | Methods for treating dravet syndrome | |
| SG11201805300QA (en) | Heterocyclic compounds as immunomodulators | |
| SG11201808582RA (en) | Pyrrolotriazine compounds as tam inhibitors | |
| SG11201805709RA (en) | Anti-pro/latent myostatin antibodies and methods of use thereof | |
| SG11201909960UA (en) | Methods for improving memory and cognition and for treating memory and cognitive disorders | |
| SG11201804132UA (en) | Eif4-a-inhibiting compounds and methods related thereto | |
| SG11201807474SA (en) | Compositions comprising coformulation of anti-pd-l1 and anti-ctla-4 antibodies | |
| SG11201906436VA (en) | Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same | |
| SG11201810280YA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| SG11201804123VA (en) | Modulators of kv3 channels to treat pain | |
| SG11201901925RA (en) | Methods of treating acute kidney injury | |
| SG11201909224QA (en) | Benzoazepine analogs as inhibiting agents for bruton's tyrosine kinase | |
| SG11201906164RA (en) | Bicyclic inhibitors of histone deacetylase | |
| SG11201811686UA (en) | 18f-labeled triazole containing psma inhibitors | |
| SG11201804587QA (en) | Isoindole compounds | |
| SG11201809882XA (en) | Pharmaceutical combinations for treating cancer | |
| SG11201809237RA (en) | Oxaborole esters and uses thereof | |
| SG11201902974PA (en) | Combination of a pd-1 antagonist and eribulin for treating urothelial cancer | |
| SG11201901320WA (en) | PPARγ AGONIST FOR TREATMENT OF BLOOD CANCERS | |
| SG11201810123SA (en) | Treatment of intrahepatic cholestatic diseases | |
| SG11201810934TA (en) | Microparticles comprising a sulphur-containing compound | |
| SG11201806622PA (en) | Egfl6 specific monoclonal antibodies and methods of their use | |
| SG11201809494VA (en) | Pharmaceutical composition comprising eteplirsen |